Skip to content

Study · Not a test of the peptide alone · 1998

3 results

New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.

Toth K, Kovacs M, Zarandi M, Halmos G, Groot K, Nagy A, Kele Z, Schally AV

The journal of peptide research : official journal of the American Peptide Society1 Feb 1998Cited by 4 (Europe PMC)

PMID9516049 (opens in a new tab)DOI10.1111/j.1399-3011.1998.tb00631.x (opens in a new tab)PepBankPUB-09516049
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Activity measurement

    In rats, the GHRH antagonist analog KT-50 showed a strong and long-term inhibitory activity in vivo.

    In plain wordsIn rats, the GHRH-blocking analog KT-50 had a strong and long-lasting inhibitory effect.

    Peptide
    Sermorelin
    Outcome
    DecreaseIn vivo inhibitory activity of GHRH antagonist KT-50
    Study

    ratn: not reported in source

    In vivo rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Analog KT-50 also exhibited a strong and long-term inhibitory activity in vivo in rats.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneEx vivo tissueActivity measurement

    In a superfused rat pituitary system, the GHRH antagonist analogs KT-30, KT-50 and KT-40 showed a high and prolonged inhibitory effect on GHRH-induced GH release.

    In plain wordsIn rat pituitary tissue in the lab, three new GHRH-blocking analogs strongly and lastingly cut growth hormone release.

    Peptide
    Sermorelin
    Outcome
    DecreaseInhibition of GHRH-induced GH release by GHRH antagonists KT-30, KT-50 and KT-40
    Study

    ratn: not reported in source

    Superfused rat pituitary system
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Peptides [PhAc-Tyr1,D-Arg2,Phe(pI)6,Abu15,Nle27]hGHRH(1-2 9)NH2 (KT-30), [PhAc-Tyr1,D-Arg2,Phe(pCl)6,Aib8,Abu15,Nle27] hGHRH(1-29)NH2 (KT-50) and [PhAc-Tyr1,D-Arg2,Phe(pCl)6,Tyr(Me)10,Abu15,Nle27]h GHRH(1-29)NH2 (KT-40) with Phe(pI)6, Aib8 or Tyr(Me)10 modifications, respectively, showed high and pr…
    1 context sentence
    Summary · context
    All the analogs were evaluated for their ability to inhibit GH release induced by hGHRH(1-29)NH2 in vitro and some were also tested in vivo.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03LabNot a test of Sermorelin aloneEx vivo tissueActivity measurement

    Most of the new GHRH antagonist analogs showed high binding affinities to rat pituitary GHRH receptors.

    In plain wordsIn rat pituitary tissue in the lab, most new GHRH-blocking analogs bound tightly to the GHRH receptor.

    Peptide
    Sermorelin
    Outcome
    Not applicableBinding affinity of new GHRH antagonist analogs
    Study

    ratn: not reported in source

    Rat pituitary GHRH receptors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Most of the new analogs showed high binding affinities to rat pituitary GHRH receptors.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.